## Review setup

- **Input scope** Abstract only
- **Assessment boundary** Feasibility and clarity of the described virtual screening protocol, as presented in the abstract
- **Shared manuscript claim summary** The authors describe a virtual screening protocol using AutoDock Vina to identify small-molecule modulators of FOXO3, based on crystal structures of the free and DNA-bound forms, with the aim of finding compounds that enhance or inhibit FOXO3 DNA-binding for therapeutic applications in cancer and aging
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or results are provided
- **Missing materials affecting confidence** Full methods, docking parameters, compound library details, scoring results, validation data, and any experimental confirmation; none of these are available from the supplied material

## Reviewer

- **Overall assessment** The abstract presents a straightforward and potentially useful protocol for structure-based virtual screening of FOXO3 modulators. The concept is sound and the target is biologically relevant. However, the abstract lacks critical technical details that would allow assessment of the protocol's validity, reproducibility, and likely success. No results are presented, so the claimed "paving the way" for novel modulator identification is not supported by evidence in the supplied material. The protocol as described is conventional and does not introduce methodological novelty beyond standard practice.
- **Who would be interested in the results, and why** Researchers in computational drug discovery, particularly those working on transcription factors as therapeutic targets, and investigators studying FOXO3 biology in cancer and aging. The protocol could serve as a practical guide for groups seeking to apply virtual screening to similar protein-DNA interaction systems.
- **Major strengths** The target is biologically important and clinically relevant. The use of both free and DNA-bound crystal structures to identify distinct binding sites is a thoughtful approach that could differentiate between enhancers and inhibitors of DNA binding. The protocol is described in a stepwise manner that is accessible to nonspecialists.
- **Major Concerns** 
  - **Concern ID** R1-M1
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Technical soundness
  - **Claim pointer** The abstract claims that a "comprehensive virtual screening" is conducted and that "highest-ranking hits" are selected and analyzed for binding modes
  - **Evidence pointer** Abstract only; location not provided
  - **Concern** No details are given on the compound library size, source, or diversity, nor on the docking protocol parameters such as exhaustiveness, grid box dimensions, scoring function settings, or validation steps such as redocking or enrichment tests. Without these, the "comprehensive" nature of the screening and the reliability of the ranking cannot be evaluated.
  - **Why it matters** Virtual screening results are highly sensitive to docking parameters and library composition. The absence of these details prevents reproducibility and undermines confidence in the hit selection. The claim that the protocol "paves the way" for identifying novel modulators is not substantiated without evidence of successful application or validation.
  - **Resolution test** Provide full methods including library details, docking parameters, validation metrics, and ideally a demonstration of the protocol on a known binder or a retrospective enrichment analysis.
  - **Concern ID** R1-M2
  - **Severity** Major
  - **Blocking** Yes
  - **Axis** Evidence sufficiency
  - **Claim pointer** The abstract implies that the protocol yields useful modulators of FOXO3 with therapeutic potential
  - **Evidence pointer** Abstract only; location not provided
  - **Concern** No results are presented. There is no indication of how many hits were obtained, whether any were tested experimentally, or whether any showed activity in cellular or biochemical assays. The therapeutic promise mentioned in the final sentence is speculative.
  - **Why it matters** A protocol paper should at minimum demonstrate that the workflow produces credible candidates. Without any results, the reader cannot judge whether the protocol is effective or whether the described approach has any practical utility.
  - **Resolution test** Include representative docking scores, structural analysis of top hits, and any experimental validation or at least a clear statement that the protocol is presented as a methodological template without validated hits.
- **Minor Comments** 
  - **Concern ID** R1-m1
  - **Severity** Minor
  - **Axis** Readability for nonspecialists
  - **Affected element** Abstract wording
  - **Evidence pointer** Abstract, final sentence
  - **Issue** The phrase "paves the way" is vague and promotional rather than descriptive of specific outcomes.
  - **Required correction** Replace with a concrete statement of what the protocol enables, such as "provides a reproducible workflow for identifying candidate FOXO3 modulators that can be tested experimentally."
  - **Concern ID** R1-m2
  - **Severity** Minor
  - **Axis** Technical soundness
  - **Affected element** Binding site identification
  - **Evidence pointer** Abstract, sentence on binding sites
  - **Issue** The abstract does not specify how binding sites were defined, for example whether they were based on known interaction hotspots, pocket detection algorithms, or literature data.
  - **Required correction** Add a brief description of the site selection criteria in the abstract or indicate that full details are in the methods section.
  - **Concern ID** R1-m3
  - **Severity** Minor
  - **Axis** Interdisciplinary readership
  - **Affected element** Software mention
  - **Evidence pointer** Abstract, AutoDock Vina mention
  - **Issue** AutoDock Vina is named but no version or citation context is given, which may hinder reproducibility for readers unfamiliar with the tool.
  - **Required correction** Include the version number and a citation in the full text, and consider mentioning it in the abstract if space permits.
- **Technical failings that need to be addressed before the case is established** R1-M1 and R1-M2 are blocking. The protocol cannot be assessed for validity or utility without docking parameters, library details, and any results or validation. The absence of these elements means the core claim of enabling modulator discovery is not established from the provided material.
- **Assessment against Nature-style criteria** 
  - Originality: Low to moderate. The approach is standard structure-based virtual screening applied to a specific target. No methodological innovation is evident from the abstract.
  - Scientific importance: Moderate. FOXO3 is a relevant target in cancer and aging, but the abstract does not demonstrate that the protocol yields biologically useful compounds.
  - Interdisciplinary readership: Limited. The abstract will appeal mainly to computational biologists and medicinal chemists; the biological significance is stated but not developed.
  - Technical soundness: Not assessable. Critical parameters and validation are missing.
  - Readability for nonspecialists: Acceptable. The abstract is clear and jargon is minimal, though some terms such as "virtual screening" and "docking" are used without definition.
- **Recommendation posture** Currently not established from the provided evidence. The protocol concept is reasonable and the target is worthwhile, but the abstract alone does not provide sufficient technical detail or results to support the claims. A revised version with full methods and at least illustrative results would be needed to assess whether the protocol is effective and reproducible.

## Risk / unsupported claims

- The claim that the protocol "paves the way for identifying novel modulators of FOXO3" is unsupported because no results or validation are presented.
- The claim that the screening is "comprehensive" is unverifiable without library details and docking parameters.
- The therapeutic potential in cancer and aging is stated as a general motivation but is not tied to any demonstrated outcome of the protocol.
- The effectiveness of the binding site identification strategy cannot be evaluated from the abstract alone.